These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 33390437)

  • 1. [Development of Biological Response Modifiers Based on Unique Medicinal Chemical Strategy].
    Hashimoto Y
    Yakugaku Zasshi; 2021; 141(1):1-13. PubMed ID: 33390437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Stage Discovery and Validation of Pharmacological Chaperones for the Correction of Protein Misfolding Diseases.
    Aubi O; Knappskog PM; Martinez A
    Methods Mol Biol; 2019; 1873():279-292. PubMed ID: 30341617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological Chaperones as Potential Therapeutic Strategies for Misfolded Mutant Vasopressin Receptors.
    Mouillac B; Mendre C
    Handb Exp Pharmacol; 2018; 245():63-83. PubMed ID: 28939971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening methods for identifying pharmacological chaperones.
    Shin MH; Lim HS
    Mol Biosyst; 2017 Mar; 13(4):638-647. PubMed ID: 28265599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological Chaperones: Beyond Conformational Disorders.
    Leidenheimer NJ
    Handb Exp Pharmacol; 2018; 245():135-153. PubMed ID: 29071508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural development of biological response modifiers based on retinoids and thalidomide.
    Hashimoto Y
    Mini Rev Med Chem; 2002 Dec; 2(6):543-51. PubMed ID: 12370039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological chaperones for the misfolded melanocortin-4 receptor associated with human obesity.
    Huang H; Wang W; Tao YX
    Biochim Biophys Acta Mol Basis Dis; 2017 Oct; 1863(10 Pt A):2496-2507. PubMed ID: 28284973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Image-based screen capturing misfolding status of Niemann-Pick type C1 identifies potential candidates for chaperone drugs.
    Shioi R; Karaki F; Yoshioka H; Noguchi-Yachide T; Ishikawa M; Dodo K; Hashimoto Y; Sodeoka M; Ohgane K
    PLoS One; 2020; 15(12):e0243746. PubMed ID: 33315900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Underlying mechanisms and chemical/biochemical therapeutic approaches to ameliorate protein misfolding neurodegenerative diseases.
    Hekmatimoghaddam S; Zare-Khormizi MR; Pourrajab F
    Biofactors; 2017 Nov; 43(6):737-759. PubMed ID: 26899445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural development of synthetic retinoids and thalidomide-related molecules.
    Hashimoto Y
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S16-23. PubMed ID: 12819930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological manipulation of rhodopsin retinitis pigmentosa.
    Mendes HF; Zaccarini R; Cheetham ME
    Adv Exp Med Biol; 2010; 664():317-23. PubMed ID: 20238031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Structural development study of a novel pharmacological chaperone for folding-defective rhodopsin mutants responsible for retinitis pigmentosa].
    Ohgane K; Dodo K; Hashimoto Y
    Yakugaku Zasshi; 2011 Mar; 131(3):325-34. PubMed ID: 21372525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural development of biological response modifiers based on thalidomide.
    Hashimoto Y
    Bioorg Med Chem; 2002 Mar; 10(3):461-79. PubMed ID: 11814832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Editorial: Molecular Vaccines Against Pathogens in the Post-genomic Era.
    Oñate AA; Wan Y; Moreno A
    Front Cell Infect Microbiol; 2019; 9():443. PubMed ID: 32039041
    [No Abstract]   [Full Text] [Related]  

  • 15. Protein Misfolding Diseases and Therapeutic Approaches.
    Yadav K; Yadav A; Vashistha P; Pandey VP; Dwivedi UN
    Curr Protein Pept Sci; 2019; 20(12):1226-1245. PubMed ID: 31187709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thalidomide as a multi-template for development of biologically active compounds.
    Hashimoto Y
    Arch Pharm (Weinheim); 2008 Sep; 341(9):536-47. PubMed ID: 18389516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein misfolding diseases: Prospects of pharmacological treatment.
    Gámez A; Yuste-Checa P; Brasil S; Briso-Montiano Á; Desviat LR; Ugarte M; Pérez-Cerdá C; Pérez B
    Clin Genet; 2018 Mar; 93(3):450-458. PubMed ID: 28671287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein degradation: a validated therapeutic strategy with exciting prospects.
    Lebraud H; Heightman TD
    Essays Biochem; 2017 Nov; 61(5):517-527. PubMed ID: 28970340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Have nanomedicines progressed as much as we'd hoped for in drug discovery and development?
    Sarmento B
    Expert Opin Drug Discov; 2019 Aug; 14(8):723-725. PubMed ID: 31161834
    [No Abstract]   [Full Text] [Related]  

  • 20. Model systems of protein-misfolding diseases reveal chaperone modifiers of proteotoxicity.
    Brehme M; Voisine C
    Dis Model Mech; 2016 Aug; 9(8):823-38. PubMed ID: 27491084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.